Study #2014-0431
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients with AML and MDS
Study Status
Open
Treatment Agent
Allogeneic Stem Cell Transplant, Busulfan, Cladribine, Fludarabine, Venetoclax
Principal Investigator
Uday Popat
Description
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to compare how well two different schedules of giving busulfan with fludarabine and cladribine before a stem cell transplant in patients with AML or MDS may help to control the disease. The safety of this drug combination will also be studied.
General Information
Disease Group: Blood And Marrow Transplantation
Treatment Agent: Allogeneic Stem Cell Transplant, Busulfan, Cladribine, Fludarabine, Venetoclax
Treatment Location: Only at MD Anderson
Sponsor: N/A
Study Status
IRB Review and Approval Date: 10/27/2014
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Blood And Marrow Transplantation
Study phase:
Phase II
Physician name:
Uday Popat
Department:
Stem Cell Transplantation and Cellular Therapy
For general questions about clinical trials:
1-877-632-6789